Skip to main content
TipRanks
Go Ultimate75% OFF

Idorsia Ltd (IDIA) AI Stock Analysis

16 Followers
CH:IDIA

Idorsia Ltd

(Six Swiss:IDIA)

Select Model
Rating:45Neutral
Price Target:CHF 4.00â–²(2.35% Upside)
Action:reiterated
Date:10/31/26

The score is primarily held down by weak financial performance—ongoing heavy losses, negative equity with high leverage, and continued cash burn—despite improving revenue and strong gross margins. Technicals add a modest drag due to the stock sitting below key longer-term moving averages with mixed momentum signals. Valuation provides limited support because the negative P/E reflects current losses and no dividend yield is available.

Positive Factors
Revenue GrowthImproving TTM revenue indicates that Idorsia is generating stronger commercial activity across its portfolio. If sustained, this growth can broaden the revenue base, improve absorption of fixed operating costs, and support greater financial contribution from existing and newly launched medicines.
Negative Factors
Negative Equity and High LeverageNegative equity and debt materially above the company’s asset base indicate weak balance-sheet resilience. This limits financial flexibility, increases dependence on creditors or external funding, and can constrain Idorsia’s ability to invest consistently in its pipeline or absorb setbacks.

Idorsia Ltd (IDIA) vs. iShares MSCI Switzerland ETF (EWL)

-25%0%25%50%75%100%125%CH:IDIA+23.28%EWL+16.05%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
CHF 1.05B
Dividend Yield
―
Average Volume (3M)
963.95K
Price to Earnings (P/E)
-3.5
Beta (1Y)
1.41
Revenue Growth
-5.32%
EPS Growth
-95.96%
Country
Switzerland
Employees
456
Sector
General
Sector Strength
55
Industry
Biotechnology

Idorsia Ltd Business Overview & Revenue Model

Company Description

Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada. The company has a clinical development pipeli...

How the Company Makes Money

Idorsia makes money primarily through (1) sales of its own medicines where it has commercialization rights and distributes products directly or via distributors in certain geographies, and (2) partnering/licensing arrangements with larger pharmaceuti...

Idorsia Ltd Earnings Call Summary

Earnings Call Date:Feb 26, 2026(Q4-2025)|% Change Since:4.21%|Next Earnings Date:Apr 25, 2024
Earnings Call SentimentPositive

The call communicated a clear operational turnaround: materially stronger commercial traction (QUVIVIQ sales > doubled, EUCAN strength), significant cost savings, improved operating losses and strengthened liquidity. These positives are balanced by remaining profitability gaps, U.S. access/regulatory uncertainty for QUVIVIQ (descheduling pending), an unfinished TRYVIO commercialization partnership process, and multi‑year timelines for key pipeline readouts (e.g., lucerastat). On balance, the company presented meaningful progress and a credible path to further de‑risking and growth, while acknowledging key near‑term risks tied to partnerships, U.S. regulatory outcomes and cash runway beyond the next inflection points.

Positive Updates

QUVIVIQ Sales More Than Doubled
QUVIVIQ product sales increased from ~CHF 60–61 million in 2024 to CHF 134 million in 2025 (≈+123%), driving net revenue to CHF 214 million and exceeding the upgraded 2025 guidance (guided CHF 130 million). Company guides QUVIVIQ sales of ~CHF 200 million for 2026 (≈+49% vs 2025).

Negative Updates

Still Operating at a Loss
Despite substantial improvement, company remains unprofitable: non‑GAAP operating loss of CHF -100 million and U.S. GAAP net loss of CHF -112 million in 2025. Financial expenses were CHF 72 million, including a CHF 61 million noncash expense tied to convertible bond restructuring.

Company Guidance

Idorsia guided QUVIVIQ sales of around CHF 200 million for 2026 (up from CHF 134M in 2025, which exceeded the prior guidance of CHF 130M) and said 2026 OpEx (including COGS) will be flat versus 2025, a combination it expects to produce the company’s first positive commercial contribution and drive overall losses lower toward profitability and cash‑flow breakeven. For 2025 the company reported net revenue of CHF 214M (including CHF 134M QUVIVIQ product sales), non‑GAAP contract revenue CHF 72M, a non‑GAAP operating loss improved to CHF ‑100M (from CHF ‑308M in 2024), U.S. GAAP EBIT loss CHF ‑33M and U.S. GAAP net loss CHF ‑112M; cost rationalization saved >CHF 80M and a Viatris negotiation (USD 100M reduction in cost‑sharing) produced a CHF 90M gain. Liquidity at year‑end was CHF 89M with access to a further CHF 80M (total CHF 169M) after drawing CHF 70M of a CHF 150M facility and raising CHF 68M net from equity, and management said it will limit guidance to the one‑year horizon given multiple upcoming inflection points (descheduling, partnerships and pipeline readouts).

Idorsia Ltd Financial Statement Overview

Summary

Revenue is improving (~10.2% TTM) and gross margin is strong (~79% TTM), but profitability and funding risk dominate: EBIT/EBITDA remain materially negative, net margin is deeply negative (~-129% TTM), equity is negative (about -1.23bn) with high debt (~1.35bn), and operating/free cash flow are still negative (OCF ~-113m; FCF ~-118m).

Income Statement

22Negative

Balance Sheet

12Very Negative

Cash Flow

18Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue220.32M221.00M112.51M152.39M97.10M35.35M
Gross Profit174.58M182.23M-67.08M145.24M90.84M17.32M
EBITDA-139.75M-45.49M-319.49M-254.55M-783.09M-588.84M
Net Income-283.72M-112.00M-263.76M-297.92M-827.90M-634.60M
Balance Sheet
Total Assets461.61M465.88M505.89M500.00M904.18M1.48B
Cash, Cash Equivalents and Short-Term Investments85.10M87.24M124.36M157.82M476.32M1.04B
Total Debt1.35B1.27B1.26B1.20B1.23B1.16B
Total Liabilities1.69B1.60B1.72B1.47B1.57B1.38B
Stockholders Equity-1.23B-1.14B-1.21B-968.72M-660.96M104.20M
Cash Flow
Free Cash Flow-117.98M-167.05M-373.23M-638.69M-886.17M-620.83M
Operating Cash Flow-112.58M-153.23M-370.23M-629.30M-859.11M-589.89M
Investing Cash Flow-1.74M4.16M305.06M632.61M743.90M-53.26M
Financing Cash Flow134.15M132.14M26.11M-197.00K162.31M604.15M

Idorsia Ltd Technical Analysis

Technical Analysis SentimentNegative
Last Price3.91

Price Trends

50DMA4.45Negative
100DMA5.23Negative
200DMA4.61Negative

Market Momentum

MACD-0.13Positive
RSI36.17Neutral
STOCH14.22Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:IDIA, the sentiment is Negative. The current price of 3.91 is below the 20-day moving average (MA) of 4.25, below the 50-day MA of 4.45, and below the 200-day MA of 4.61, indicating a bearish trend. The MACD of -0.13 indicates Positive momentum. The RSI at 36.17 is Neutral, neither overbought nor oversold. The STOCH value of 14.22 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CH:IDIA.

Idorsia Ltd Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

CH:IDIA against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
CH:BSLNCH:BSLN71OutperformCHF 881.42M17.07――4.74%-28.96%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
CH:SANNCH:SANN52NeutralCHF 231.32M-6.41354.99%―107.08%55.54%
CH:NWRNCH:NWRN45NeutralCHF 189.45M-6.41258.11%―-82.88%-212.48%
CH:IDIACH:IDIA45NeutralCHF 1.06B-3.52――-5.32%-95.96%
CH:ADXNCH:ADXN41NeutralCHF 4.33M-0.69-204.04%―-50.34%4.75%
CH:MOLNCH:MOLN38UnderperformCHF 100.13M-1.78-79.25%――16.86%

* General Sector Average

Performance Comparison

-50%0%50%100%CH:IDIACH:ADXNCH:MOLNCH:BSLNCH:NWRNCH:SANNDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
CH:IDIA and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
CH:IDIAIdorsia Ltd3.910.7423.48%
CH:ADXNAddex Therapeutics Ltd0.03-0.03-43.86%
CH:MOLNMolecular Partners2.40-0.98-28.99%
CH:BSLNBasilea Pharmaceutica72.7025.9555.51%
CH:NWRNNewron Pharmaceuticals SpA8.65-7.19-45.39%
CH:SANNSanthera Pharmaceuticals Holding Ag14.623.9036.38%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 31, 2026